ARTICLES

203  **Protecting Scientific Integrity:** The Commercial Speech Doctrine Applied to Industry Publications  *Joanna K. Sax*

225  **Off-Label Drug Use and Promotion:** Balancing Public Health Goals and Commercial Speech  *Aaron S. Kesselheim*

258  **Commercial Speech and Off-Label Drug Uses:** What Role for Wide Acceptance, General Recognition and Research Incentives?  *Margaret Gilhooley*

278  **The Ban on “Off-Label” Pharmaceutical Promotion:** Constitutionally Permissible Prophylaxis Against False or Misleading Commercial Speech?  *Kate Greenwood*

299  **The Commercial Speech Doctrine in Health Regulation:** The Clash Between the Public Interest in a Robust First Amendment and the Public Interest in Effective Protection from Harm  *David Orentlicher*

315  **Off-Label Prescription Advertising, the FDA and the First Amendment:** A Study in the Values of Commercial Speech Protection  *Coleen Klasmeier and Martin H. Redish*

358  **The Money Blind:** How to Stop Industry Bias in Biomedical Science, Without Violating the First Amendment  *Christopher T. Robertson*

388  **Can Speech by FDA-Regulated Firms Ever be Noncommercial?**  *Nathan Cortez*
NOTES AND COMMENTS

422  No Need for More Regulation: Payors and Their Role in Balancing the Cost and Safety Considerations of Off-Label Prescriptions  Amy E. Todd

444  You Can’t Say That on Television: Constitutional Analysis of a Direct-to-Consumer Pharmaceutical Advertising Ban  Lia Mulligan